Pregabalin Capsule
Product Images NDC 71335-1476

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1476). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351476)

Label for PREGABALIN capsules USP 75 mg by Bryant Ranch Prepack. The label shows the product strength as 75 mg, includes a barcode, and states the package contains 30 capsules. It has storage instructions and a note to keep out of children's reach. The label also features the BRP Pharmaceuticals logo and the NDC 71335-1476.*

FDA Label Image

Label (Lbl7133514762)

Label for Pregabalin 75 mg (CV) Capsule, packaged by Bryant Ranch Prepack in Burbank, CA. The label states it is comparable to Lyrica 75 mg (CV) Capsule by Laurus Labs Limited and is marked RX only. NDC is 71335-1476-1, with lot number 1523487. The label includes storage instructions at 20°-25°C and a warning to keep drugs out of reach of children.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure diagram of the active ingredient Pregabalin, showing its molecular components and bonds.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

Mathematical formula illustrating the calculation of creatinine clearance (CLCr), factoring in age, weight, serum creatinine levels, and an adjustment for female patients. This image is a diagram relevant to clinical pharmacokinetics, but does not depict a chemical structure.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin dosed three times a day at 200 mg, 100 mg, 25 mg, and placebo. The graph compares effectiveness of different dosages for pain improvement over a continuum of baseline improvement percentages.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A cumulative distribution plot showing percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day to placebo. The graph illustrates a higher percentage of patient improvement with Pregabalin across various pain improvement thresholds.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares pregabalin at 75 mg, 150 mg, and 300 mg dosages taken twice a day against placebo, illustrating performance differences across these groups.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph depicting the percent of patients improved on the y-axis versus the percent improvement in pain from baseline on the x-axis. The chart compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing higher improvement percentages for Pregabalin groups across increasing pain improvement thresholds.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The vertical axis represents percent of patients improved, while the horizontal axis shows percent improvement in pain from baseline, ranging from 0 to 100%.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

Bar chart comparing responder rates (%) in Studies E1 and E3. The chart shows placebo versus different doses of pregabalin (50 mg/day to 600 mg/day) with responder rates increasing with dose. Participant numbers (N) are shown below each dose. The chart highlights statistically significant differences versus placebo.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg/day, comparing data from four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID. Significant p-values are shown at various doses, indicating statistical results at measured dose points.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line chart comparing percent improvement in pain from baseline to the percent of patients improved for Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and placebo. Four trend lines are shown indicating patient response rates across pain improvement percentages from 0 to 100.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A survival curve chart showing the estimated percentage of subjects without LTR over a 180-day period, comparing Pregabalin and placebo. The x-axis represents days from 0 to 180, and the y-axis shows the estimated percentage of subjects without LTR from 0% to 100%. Two lines are depicted: a solid line for Pregabalin and a dashed line for placebo, illustrating their respective trends over time.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing the percent of subjects improved from baseline to Week 12 in a study of Pregabalin versus placebo. The x-axis shows percent improvement ranging from 0 to 100, and the y-axis represents the percent of subjects improved from 0 to 100 percent. Two lines plot improvement: a solid line for Pregabalin showing higher improvement rates, and a dashed line for placebo showing lower improvement rates.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

Chart comparing percent of subjects improved from baseline to Week 16 BOCF for Pregabalin and placebo. The x-axis shows percent improvement categories from >0 to 100, and the y-axis shows percent of subjects improved. Pregabalin is represented by a solid line, which consistently lies above the dashed line representing placebo, indicating higher improvement rates with Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.